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Abstract
Background: Systematic review and meta-analysis currently underpin much of evidence-based
medicine. Such methodologies bring order to previous  research, but future  research planning
remains relatively incoherent and inefficient.
Methods: To outline a framework for evaluation of health interventions, aimed at increasing
coherence and efficiency through i) making better use of information contained within the existing
evidence-base when designing future studies; and ii) maximising the information available and thus
potentially reducing the need for future studies.
Results: The framework presented insists that an up-to-date meta-analysis of existing randomised
controlled trials (RCTs) should always be considered before future trials are conducted. Such a
meta-analysis should inform critical design issues such as sample size determination. The contexts
in which the use of individual patient data meta-analysis and mixed treatment comparisons
modelling may be beneficial before further RCTs are conducted are considered. Consideration
should also be given to how any newly planned RCTs would contribute to the totality of evidence
through its incorporation into an updated meta-analysis. We illustrate how new RCTs can have
very low power to change inferences of an existing meta-analysis, particularly when between study
heterogeneity is taken into consideration.
Conclusion: While the collation of existing evidence as the basis for clinical practice is now
routine, a more coherent and efficient approach to planning future RCTs to strengthen the
evidence base needs to be developed. The framework presented is a proposal for how this
situation can be improved.
Background
Over the last two decades we have experienced the evi-
dence-based medicine (EBM) revolution [1] in how inter-
ventions are evaluated and administered. Central to this
initiative is the use of systematic review and meta-analysis
of randomised controlled trials (RCTs), since they provide
the highest level of evidence regarding effectiveness of
interventions. This has led to an increasing reliance on the
use of meta-analysis to inform clinical decision-making at
both the policy and individual level. Additionally, it is
often stated that one of the outputs of a systematic review
is to identify "gaps" in the current evidence base, and this
is made explicit in the aims of the Cochrane Collabora-
tion [2]. To this end, a systematic review should inform
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future research and, indeed, the QUOROM (recently
renamed PRISMA) statement checklist [3] includes the
item "suggest a future research agenda". Not only is this
desirable, but doing otherwise is incoherent and will lead
to inefficiency through the design of sub-optimal RCTs in
the future [4]. However, recommendations currently
found in systematic reviews regarding research needs,
although useful, [5] could be made more informative and
explicit.
Further, presently, the vast majority of meta-analyses are
produced as observational by-products of the existing lit-
erature; little or no consideration of the overarching
(meta-) analysis is made at the design stage of the individ-
ual component studies that eventually make up the meta-
analysis. This is despite the fact that in many instances the
updated meta-analysis will be of central importance and more
influential than the results of the new studies on their own (as
implied by the position of meta-analyses at the top of
hierarchies of types of evidence[6]). If we accept this point
of view, then it is coherent to design and power a new trial
based on the predicted results of the updated synthesis of
the existing evidence, rather than powering the new trial
on an isolated analysis [7].
To address this incoherence, we propose a cyclic frame-
work for evaluation of interventions, incorporating
emerging methodologies, aimed at increasing coherence
and efficiency through i) making better use of informa-
tion contained within the existing evidence-base when
designing future studies; and ii) maximising the informa-
tion so gained and thus potentially reducing the need for
future RCTs, and the costs and delays they entail.
If implemented, we believe this would go some way to
ensuring future research is more evidence-based. As well
as reducing the economic cost of gaining further informa-
t i o n  ( w h i c h  i s  w h a t  w e  i m p l y  b y  e f f i c i e n c y  h e r e )  w e
believe such methods also potentially have benefits from
an ethical perspective by maximising the information
gained for each new patient randomised. Figure 1 summa-
rises the whole cyclic framework; the exposition that fol-
lows fleshes out the three stages contained within the two
distinct parts to the framework outlined in the Figure.
Methods
Part 1: Analysis of the existing evidence-base
Stage 1: Before any new study is designed, it is important
that an up-to-date systematic review and meta-analysis is
identified or carried out, as those which are published
potentially go out of date quickly [8].
Even if this does not answer the clinically important ques-
tions of interest, it may be possible to answer them
through further analysis of the existing evidence-base
(Stage 2). Several evidence synthesis models are described
together with their potential advantages over standard
meta-analysis for answering increasingly important clini-
cal questions. These methods are included in the flow-
chart (Figure 1), indicating how they fit into the cyclic
approach to research design and analysis, as such models
can be used as the basis of designing of future studies in
the same way as meta-analysis can be (see Stage 3 in Part
2 below).
Detailed analysis of patient subgroups: obtaining and analysing 
Individual Patient Data (IPD)
If there is still uncertainty regarding the effectiveness of an
intervention in certain population subgroups (an increas-
ingly important issue as we move towards individualising
treatment regimes) it may be worthwhile obtaining and
analysing individual patient data (IPD) [9] since this
would allow a much more powerful exploration of patient
characteristic by treatment interactions [10]. Although such
analyses are more costly than meta-analyses based on
summary statistics, they may still be considered "good
value" compared to conducting future trials. Further,
"half-way house" alternatives to obtaining the IPD, such
as requesting summary statistics on specific subgroups of
patients, may provide a useful compromise with respect to
cost and power [11]. In the past, meta-analysis of IPD
were sometimes hampered by the lack of availability of
data from a proportion of the relevant studies, but meth-
ods are being developed [12] to combine IPD and sum-
mary data allowing most efficient use of the available data
in such situations. Such methods have been used to
explore the influence of socio-economic variables on
home safety practices [13] including the safe storage of
matches or lighters considered in the results section. How-
ever, as documented elsewhere, [14] methods for identify-
ing subgroup effects can be abused and results over-
interpreted and measures should be taken to avoid this.
Synthesis of all competing interventions: Mixed treatment 
comparisons
An important development in evidence synthesis method-
ology over recent years is mixed treatment comparison
(MTC) modelling [15-18]. Such an approach allows evi-
dence networks in which trials making different compari-
sons to be synthesised together allowing a coherent
picture of the effectiveness of all treatment options to be
created. This allows i) the estimation of comparisons for
which there is no direct randomised evidence – enabling
us to answer such clinically relevant questions as the prob-
ability any one treatment is superior to the rest; ii) an
increase in precision of treatment effects where there are
direct estimates by including the indirect comparisons;
and iii) an exploration of the consistency of the whole evi-
dence-base for a particular condition. The potential toBMC Medical Research Methodology 2009, 9:29 http://www.biomedcentral.com/1471-2288/9/29
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Flow-chart for proposed cyclic, coherent and efficient research synthesis/research design strategy for answering questions of  clinical importance Figure 1
Flow-chart for proposed cyclic, coherent and efficient research synthesis/research design strategy for answer-
ing questions of clinical importance. * Ideally based on a clinically-centred criteria such as limits of equivalence (rather 
than statistical significance).
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amalgamate existing meta-analyses, [19] as well as create
new syntheses from the ground-up is considerable.
Utilising other evidence synthesis models
There is also scope for using other evidence synthesis
structures to answer questions of clinical importance, and
these are reviewed in detail elsewhere [20]. For example,
the use of surrogate endpoints has received much atten-
tion recently [21] and synthesis models have been
described which combine information on both interme-
diate and clinical outcomes using a "chain of evidence"
approach [22] making efficient use of multiple sources of
information. Further models, utilising economic data are
considered in the discussion.
Part 2 (including Stage 3): Designing future research more 
efficiently
Role of systematic review and meta-analysis in the design of future 
research
Although, in some contexts, it is becoming obligatory to
consider the current evidence-base when designing new
studies (e.g., in the UK applicants to the Medical Research
Council/National Institute for Health Research for clinical
trial support are prompted to provide evidence from sys-
tematic reviews of the need for their proposed trial). Con-
sidering how the results of newly completed studies
update the evidence-base [23] has become a requirement
when publishing RCTs in some journals including JAMA
and The Lancet [24] and encouraged by others. However,
there is still a rift in the cyclic process of designing new
studies using current knowledge, synthesising the results
of such studies with the existing research and then design-
ing further studies informed by these results to answer the
questions of clinical importance (Figure 1). Evidence
exists to suggest that such a cyclic process is not adhered
to routinely. For example, Cooper et al [25]. found that
only 8 out of 24 trialists (33%) consulted the Cochrane
(or other) systematic review (in existence by 1996), which
their new RCT would ultimately update (in either 2002 or
2003), when designing their RCT. One of the reasons new
research may not be designed as coherently as it could
have been, using the existing evidence-base, is that there is
remarkably little written on how to do this, at least quan-
titatively. While it is already widely recognised that previ-
ous research may assist in defining such important details
as i) outcome definitions; ii) hypotheses under test, as
well as making sure pitfalls of previous studies are
avoided, [4] less consideration has previously been given
to quantitative design issues, such as the sample size of a
future RCT.
As noted in the introduction, little consideration of the
overarching (meta-) analysis is made at the design stage of
the individual component studies that eventually make
up the synthesis, despite the fact that the updated meta-
analysis may be more influential than the results of the
new studies on their own. Therefore, it is coherent to
design and power a new trial based on the predicted
results of the updated meta-analysis (or related synthesis
model) including the new trial (Stage 3 in Figure 1) [7].
Although effectiveness of an intervention is still often
defined in terms of its statistical significance, it is also well
appreciated that p-values are limited in their usefulness
[26]. A particular limitation is that interventions that are
statistically significant may not be clinically important. In
such circumstances, data collection should stop when it
has been ascertained that, even if an effect exists, it is
unlikely to be clinically important; this will be prior to the
null hypothesis (of no treatment effect) being rejected. If
this does not happen then much resource could be wasted
'chasing' sub-clinical or non-existent effects in future
research.
An alternative to statistical significance, which addresses
this issue, is to define limits of equivalence using pre-spec-
ified criteria to define effect sizes for which a new treat-
ment is clinically superior to the existing one [7]. If this
were done then design decisions would be based around
the estimate of effect and associated uncertainty. For
example, data collection could stop once it was 95% cer-
tain that the effect size was within or outside the limits of
equivalence. (N.B. this notion is closely related to how
equivalence trials are currently designed [27]). Despite
obvious challenges in definitively choosing values for the
limits of equivalence, the authors are in support of the use
of this type of criterion as an alternative to arbitrary cut-
offs on the p-value scale for decision making.
In the results section we consider alternatives to the tradi-
tional sample size calculation which use the current evi-
dence-base as their basis, including approaches that
consider how the new trial results will impact on the total-
ity of the evidence-base and use criteria other than statis-
tical significance.
There is still the need to design the first RCT, when no pre-
vious ones have been conducted. In such cases the use of
traditional sample size calculations may be appropriate.
For example, designing a trial with favourable power to
detect the smallest difference that would be clinically
worthwhile using evidence from related studies (e.g. drugs
in the same class etc.), ideally taking the uncertainty in the
estimation into account [28]. However, there may be
advantages in formalising this procedure through further
methodological development. This could help avoid sam-
ple size calculations being based on inflated control group
rates and excessively large treatment effects. There is even
evidence to suggest sample size calculations are some-
times "reverse engineered", with the treatment differenceBMC Medical Research Methodology 2009, 9:29 http://www.biomedcentral.com/1471-2288/9/29
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assumed in the power calculation being derived from the
given economic/feasibility restrictions on the researchers
[29]. For whatever reason, when this occurs, the RCT is
likely to be underpowered and this is not an efficient
(even ethical) use of resources.
As with more ad hoc updating of meta-analyses, the threat
of spurious results being obtained, due to multiple analy-
ses being conducted as data accumulates within the
framework, remains a possibility. Previous authors have
considered this issue for updating of meta-analyses
assuming fixed effect [30] and heterogeneous data accu-
mulation, [31] (Higgins JPT, Whitehead A, Simmonds M:
Sequential methods for random-effects meta-analyses,
submitted) adapting formal monitoring procedures ini-
tially developed for single RCTs. We would fully support
the use of such approaches in conjunction with the frame-
work presented (as we would the adaptation of methods
for adaptive trial design used to maintain type-1 error
rates [32]).
Results
Estimating the power of a new trial, based on statistical 
significance, using the results of an existing meta-analysis
Figure 2 presents an existing meta-analysis, taken from a
recent Cochrane review [13], of the success of households
at storing matches or lighters out of the reach of children
following education and/or provision of safety equip-
ment. A fixed effect analysis produces an odds ratio of
1.10 (95% CI 0.79 to 1.54). Hence, although the point
estimate suggests a potential modest benefit of the inter-
vention, the result is non-significant at the 5% signifi-
cance level (p = 0.56) and the confidence interval includes
one, suggesting a need to collect more evidence before
firm conclusions on the effectiveness of the intervention
can be made. Alternative approaches to estimating the
sample size for a new trial are outlined below.
Powering a new trial in isolation, based on statistical 
significance, using the meta-analysis
A new trial could be designed with the expected treatment
effect being equal to the pooled estimate of effect from the
meta-analysis. Although traditionally sample size calcula-
Fixed effect meta-analysis from home safety education and provision of safety equipment for injury prevention systematic  review for the outcome storage of matches or lighters out of reach of children Figure 2
Fixed effect meta-analysis from home safety education and provision of safety equipment for injury prevention 
systematic review for the outcome storage of matches or lighters out of reach of children.
Overall  (I-squared = 44.7%, p = 0.124)
Hendrickson (2002)
Study ID
Kendrick (1999)
Sznajder (2003)
King (2001)
Kelly (1987)
1.10 (0.79, 1.54)
3.82 (0.74, 19.70)
OR (95% CI)
0.28 (0.06, 1.35)
9.19 (0.48, 175.58)
1.04 (0.72, 1.51)
1.30 (0.33, 5.13)
556/985
Events,
36/38
Treatment
356/363
47/47
66/482
51/55
554/979
Events,
33/40
Control
364/366
46/50
62/469
49/54
100.00
%
2.53
Weight
10.43
0.70
80.97
5.37
1.10 (0.79, 1.54)
3.82 (0.74, 19.70)
OR (95% CI)
0.28 (0.06, 1.35)
9.19 (0.48, 175.58)
1.04 (0.72, 1.51)
1.30 (0.33, 5.13)
556/985
Events,
36/38
Treatment
356/363
47/47
66/482
51/55
Favours control   Favours intervention 
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tions are often based on the smallest clinically worthwhile
effect size, the same mathematical approach can be
applied using the meta-analysis point estimate instead
since this can be considered the expected treatment effect.
Specifically, Type I and II error rates can be specified in the
usual way and sample sizes can be derived using standard
formulae [33]. For the example meta-analysis, if we wish
to have 80% power to detect an odds ratio of 1.10 at the
5% level in a new trial, assuming the baseline event rate in
the new trial equal to the average observed in the meta-
analysis, (N.B. this is also assumed in the alternative
approaches considered below) approximately 1200 sub-
jects per trial arm would be required. Clearly, in this and
the examples which follow, improved, context-specific,
estimates of the control group event rate may be available,
for example, through the use of relevant observational
data, ideally, measured in the proposed trial population
[29]. If so, we would encourage the use of such estimates
as an alternative to averaged estimates.
Powering a new trial to update the existing meta-analysis 
based on statistical significance
As argued in the main text, it is more coherent to power a
trial with respect to the impact it has on a potential future
updated meta-analysis if this will be used to make deci-
sions. Recently, we have described a method to do this [7]
which uses simulation methods and takes into account
the uncertainty in the pooled meta-analysis estimate. For
the example meta-analysis, the sample size for a new trial
to provide 80% power to yield a fixed effect meta-analysis
(i.e. ignoring between study heterogeneity) with a statisti-
cally significant result at the 5% significance level would
require 14,000 subjects in each arm. This number is so
large, for this example, because of the small effect size esti-
mated from the meta-analysis (i.e. if an intervention effect
does exist, it is likely to be small) and the large uncertainty
in its estimation. The sample size derived by this method
can be larger or smaller than that calculated using stand-
ard methods depending on the treatment effect and corre-
sponding uncertainty obtained from the meta-analysis of
the existing studies. The greater the amount of existing evi-
dence, the greater the 'inertia' to change by new evidence
in the pooled effect.
Although the above calculation ignored heterogeneity
between study results in the meta-analysis, in fact, moder-
ate heterogeneity is present (suggested by an I2 value [34]
of 44.7%) and this should be taken into consideration
when designing future studies. Ideally, it is highly desira-
ble to try and explain such heterogeneity by including
study-level covariates in the meta-analysis model [35] or
conducting subgroup analyses (or obtaining individual
patient data (IPD) as discussed in Part 2). If study/patient
characteristics are identified which appear to influence
outcome, then obviously these factors need to be consid-
ered when designing a new study. However, such endeav-
ours, based on summary level data are often limited, as
they are restricted by the small number of studies typically
included in a meta-analysis [10]. Residual heterogeneity
can be accounted for using a random effects model. One
of the implications of including a random effect in a meta-
analysis model is that it acts as a limiter on the magnitude
of the influence any individual study has on the analysis.
This implies that when heterogeneity is present, even a
very large new study may have very little (even zero – see
below) power to change statistical inferences in a meta-
analysis (!) since its allocated weight will be relatively
small, and inevitably under-powered in the meta-analysis
framework (even though it could have considerable
power when analysed on its own). This is indeed the case
for the storage of matches example; given the degree of het-
erogeneity, no single further study, irrespective of its size, has
any power to produce a significant pooled result at the 5% level
when included in the updated meta-analysis.
Famous examples of this phenomenon exist in the litera-
ture. For example, in a random effects meta-analysis of tri-
als of magnesium trials in myocardial infarction, [36] the
mega-trial ISIS-4 includes 93% of the total number of
patients randomised across all trials but receives only 17%
of the weight in a random-effects meta-analysis.
An implication of this is that multiple small new studies
can, in aggregate, be weighted more than a single large
study containing the same number of subjects as the
smaller studies in total in an updated meta-analysis; this
has important implications for design of future studies. A
heuristic explanation for this finding is that multiple esti-
mates can better estimate the distribution  of effects
assumed under a random effects model. We do not
believe this point is widely appreciated as it should be and
it is seldom taken into consideration when new studies
are designed.
Powering a new study to update the existing meta-analysis 
based on limits of equivalence
In order to use this approach it is necessary to specify
effect sizes which are too small to be important, that is, in
this context, effect sizes for which it would not be consid-
ered worthwhile to offer education/provision of safety
equipment to prevent thermal injuries. Using simulation,
estimation of power for such criteria is straightforward as
illustrated elsewhere [7]. For example, if it were consid-
ered that odds ratios of less than 1.5 represent non-worth-
while effect sizes, approximately 850 subjects in each arm
of a new trial would be required to have 80% power to rule
out effect sizes greater than this with a type 1 error of 5%
under a random effects model. (I.e. this further trial
would be done with a view to definitively establishing theBMC Medical Research Methodology 2009, 9:29 http://www.biomedcentral.com/1471-2288/9/29
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effectiveness of the intervention is not of a worthwhile
magnitude.)
Discussion
In this paper we have presented a coherent and efficient
framework for research design underpinned by evidence
synthesis methodologies. We have kept technical details
to a minimum, although these can be found in the cited
articles. While the context considered throughout is the
design of RCTs to evaluate interventions, the framework
and methodologies are relevant, and readily modifiable,
to other research areas such as epidemiology.
There have been previous efforts to designing multiple
studies in a coherent manner. For example when carrying
out multiple studies simultaneously, prospective meta-
analyses [37,38] have been used to design a collection of
studies with the prospect of an eventual meta-analysis in
mind, so that important elements of study design comple-
ment each other across studies [39]. While our sequential
approach complements this simultaneous design
approach, it will be applicable in a broader range of con-
texts. Others have also considered the use of (fully) Baye-
sian methods which utilise previous evidence to derive
prior distributions to inform sample size calculations for
new studies, [40] but the updating of evidence is via Bayes
Therom and not via meta-analysis and hence does not
model heterogeneity in the same way.
For the framework and sample size calculations of future
trials to be valid, the meta-analysis it includes also needs
to be valid. Therefore, the usual threats to the validity of a
meta-analysis, including the threat of publication bias
and biases induced by the inclusion of sub-optimally con-
ducted trials, need to be considered and ideally addressed
using methods which are continually evolving [41,42]. A
particular threat to the sequential framework is time-lag
bias, with interesting results published more quickly than
the rest. Recursive cumulative meta-analysis, or meta-
regression, could be used to check for this and for other
reasons why effect sizes may systematically change over
time [43].
Returning to the magnesium for myocardial infarction
meta-analysis, in this example, the mega-trial ISIS-4 pro-
duced results which were inconsistent with the previous
trials by suggesting magnesium was ineffective. This is an
example where a random effect meta-analysis model
would not appear to be a suitable model for this data and
a more measured analysis would consider both study
sample size and patient baseline risk as important covari-
ates which need to be taken into consideration [36]. This
highlights the challenge of needing to choose an appro-
priate model that not only combines the previous evi-
dence, but the future evidence also. Further, generally, too
little thought has gone into interpretation when (unex-
plainable) heterogeneity exists in random-effects meta-
analysis; although this is starting to be addressed [44].
When such heterogeneity exists it can seriously diminish
the impact future research will have (e.g. even the huge
ISIS-4 trial had minimal impact on the existing evidence
base); although this is an issue with random effect models
rather than our framework per se. This can be viewed as
undesirable, and we are certainly not opposed to the
exploration of approaches to dealing with heterogeneous
data that do not involve random effects.
We acknowledge that before widespread adoption of the
framework can take place careful development of case
studies is desirable to consider specific implications in
more detail (e.g. such as the role of confirmatory trials)
and further refine the methods, especially when using evi-
dence structures other than standard meta-analysis to
inform future research. In particular, the evaluation of
such methods in the pharmaceutical industry will also
need careful consideration to identify any restrictions
placed on approaches to study design by the regulatory
bodies. Further, we are also aware of a potential tension
between trialists who may believe their trials examine
unique hypotheses (e.g. using modified interventions, or
different populations from those used previously) and
thus be reticent about the approach compared to the
meta-analyst who takes a more holistic approach to eval-
uation. Trials which may be underway, but which have
not yet reported their results, would need building into
the simulation modelling, if they exist. The dilemmas fac-
ing trialists, when results of other trials become available
during the duration of their trial, have been described pre-
viously [45]. Further, retrospective assessment of the use
of such data via a cumulative meta-analysis to design and
monitor a further trial has been proposed, [46] and is con-
sistent with the evidence-based principles of the frame-
work considered here. Additionally, issues relating to the
monitoring of (individual) future trials would need care-
ful consideration. Currently, we encourage researchers
powering their studies using traditional methods to carry
out a simultaneous assessment of how such studies would
impact on existing meta-analyses so they are at least aware
of the potential impact (or lack of) their study will have
on the total evidence-base.
We would like to think in the future that the framework
could be refined as relevant methodologies improve. For
example, we welcome the day when IPD for all trials is
made publicly available and reliance on published data
could be removed from the framework. Additionally, evi-
dence from observational studies may exist which could
augment that available from the RCTs. While methodolo-
gies to synthesise both are in development [47] we believe
they are some way off being recommended for routineBMC Medical Research Methodology 2009, 9:29 http://www.biomedcentral.com/1471-2288/9/29
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use, but as approaches to adjust for biases develop [48] we
hope this situation will change in the future. Indeed, we
hope the publication of this paper will pave the way for a
full scale pilot of the framework in a real clinical example.
This would further identify the benefits and shortcomings
of the approach (which may be addressable by further
refinement and modification).
By considering equivalence limits for meta-analysis,
emphasis is moved from statistical to clinical significance.
However, often, several outcome measures (including
those relating to adverse events) will be relevant to the
decision on which treatment is superior. For this purpose,
decision models can be built which include results from
meta-analyses of multiple outcome measures [49,50].
Similarly, often, it will be necessary to consider cost-effec-
tiveness of an intervention, which adds a further dimen-
sion of evidence which needs considering. Again, decision
models are often developed in order to do this. In many
instances, it will be appropriate to use parameter esti-
mates derived from meta-analyses in such models [51]
and as such they can be thought of as extended evidence
synthesis models. Such models could be directly incorpo-
rated into the framework (Figure 1) alongside the IPD and
MTC models.
A further step still would be to use a full decision theoretic
approach to resource allocation and decision making
[52]. Expected value of information (EVI) approaches to
decision making are being developed [53,54]. Here, the
potential payoffs of carrying out research in monetary
terms are considered alongside the expense of carrying out
the research. Although conceptually appealing, there are
still difficult issues to resolve such as the need to estimate
parameters in the model on which it is difficult to collect
information. Our approach could be considered a less
radical and (currently) more practical "halfway-house"
between current practice and this ideal.
Conclusion
While the collation of existing evidence as the basis for
clinical practice is now routine, a more coherent and effi-
cient approach to planning future RCTs to strengthen the
evidence base needs to be developed. The framework pre-
sented is a proposal for how this situation can be
improved.
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